The National Institutes of Health (NIH) has awarded a grant to researchers at Carnegie Mellon…
Articles by Joana Carvalho, PhD
LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), continues to show promising results in…
A Phase 3 trial is testing a higher dose of Adakveo (crizanlizumab), the first approved targeted treatment for…
Oxbryta (voxelotor), the first treatment for sickle cell disease that addresses a root cause, will continue to be…
Adakveo (crizanlizumab) is an “important addition” to the care of sickle cell disease, a safe and effective…
A first targeted treatment for sickle cell disease (SCD) — Adakveo (crizanlizumab), by Novartis, that works…
Scientists have found a way to increase the effectiveness of the gene-editing tool CRISPR/Cas9 that one day may be…
A technique called zinc finger nuclease (ZFN) gene editing technology can be used to modify immature red blood cells…
The prenatal test UNITY, which uses maternal blood samples, is effective in screening for sickle cell disease (SCD),…
The U.S. Food and Drug Administration (FDA) is giving priority review, as requested, to Global Blood Therapeutics‘ application…